ArticleInflammatory bowel diseases2025
Guidance for Fecal Microbiota Transplantation Trials in Ulcerative Colitis: The Second ROME Consensus Conference.
Article in Inflammatory bowel diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Neglected kingdoms: the gut virome, mycobiome and their role in inflammatory bowel disease.Gut microbes · 2026Review
- A functional immune-based platform for donor-recipient matching in faecal microbiota transplantation for inflammatory bowel disease.EBioMedicine · 2026Article
- Specificity vs. Synergy Between Single-Strain and Multi-Strain Probiotics for Ulcerative Colitis Treatment: A Review of the Literature.Biomedicines · 2026Review
- Emerging Role of Gut Microbiota in Modulating Response to Therapies in IBD.Microorganisms · 2026Review
- Diet and Gut Microbiota in Inflammatory Bowel Disease: A Clinical and Nutritional Perspective.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Pulmonary injury in inflammatory bowel disease: intestinal barrier disruption, gut-lung axis remodeling, and treatment-related lung toxicity.Frontiers in immunology · 2026Review
- Fecal microbiota transplantation in ulcerative colitis: mucosal immune mechanisms and precision microbiota therapy.Frontiers in immunology · 2026Review
- Optimized fecal microbiota transplantation using membrane-filtered bacterial concentrates as adjunctive therapy for mild-to-moderate ulcerative colitis: a retrospective cohort study.Frontiers in microbiology · 2026Article
- One therapy, many targets: redefining ulcerative colitis treatment through fecal microbiota transplantation.Therapeutic advances in gastroenterology · 2026Review
- Fecal microbiota transplantation in ulcerative colitis: evidence, mechanisms, and practice considerations.Therapeutic advances in gastroenterology · 2026Review
- Enteric nervous system as a therapeutic target in gastrointestinal disorders.World journal of gastrointestinal pharmacology and therapeutics · 2025Article
- Advances in capsule-based fecal microbiota transplantation: clinical applications and innovations.Journal of translational medicine · 2025Review
- The Gut Microbial Metabolite Indole-3-Acetic Acid Reprograms Systemic Homeostasis and Ameliorates IBD-Associated Cachexia Independent of Food Intake.International journal of molecular sciences · 2025Article
- Combination strategies of gut microbiota in cancer therapy through metabolic reprogramming and immune remodeling.Cell communication and signaling : CCS · 2025Review
- Gut Microbiota Modulation in IBD: From the Old Paradigm to Revolutionary Tools.International journal of molecular sciences · 2025Review
- Gut Microbiome and Paediatric Inflammatory Bowel Disease: Emerging Mechanistic and Therapeutic Insights Into Pathogenesis and Microbiota-Based Approaches.IET systems biologyReview
- Fecal Microbiota Transplantation for Inflammatory Bowel Disease: Where We Stand and What Is Next.Inflammatory intestinal diseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
48 authors.
Funding
Abstract
backgroundFecal microbiota transplantation (FMT) is emerging as a potential treatment modality for individuals living with inflammatory bowel disease (IBD). Despite its promise, the effectiveness of FMT for treating IBD, particularly for ulcerative colitis (UC), still requires thorough clinical investigation. Notwithstanding differences in methodologies, current studies demonstrate its potential for inducing remission in UC patients. Therefore, standardized and robust randomized clinical trials (RCTs) are needed to further support its efficacy for managing UC. The aim of the second Rome Consensus Conference was to address gaps and uncertainties identified in previous research regarding FMT and to offer a robust framework for future studies applied to the treatment of UC.
methodsGlobal experts in the field of clinical IBD, mucosal immunology, and microbiology (N = 48) gathered to address the need for standardized clinical trials in FMT investigation. The group focused on key issues, such as stool donation, donor selection, characterization of fecal biomass, potential administration routes, as well as the process of induction, maintenance, and endpoint readouts. RESULTS AND
conclusionsThe consensus achieved during this conference established standardization of methods and protocols to enhance the current quality of research, with the aim of eventual implementation of FMT in managing UC and the ultimate goal of improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.